Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Paroxetine Mesylate

FDA-approved product (tablet, oral), marketed as Paroxetine, Paroxetine Hydrochloride, Paxil and 4 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Paroxetine Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anxiety disorder
  • Depressive disorder
  • Major depressive disorder
  • Menopause
  • Obsessive-compulsive disorder
  • Panic disorder
  • Post-traumatic stress disorder
  • Social anxiety disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective serotonin reuptake inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli23.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae19.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Paroxetine Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Paroxetine Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder

    NCT00540098 · start 2001-09

    Registered record
    Registry ID
    NCT00540098
    Conditions
    Panic Disorder
    Interventions
    paroxetine + aerobic exercise; Paroxetine + relaxation; Placebo + aerobic exercise; Placebo + relaxation
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2001-09
    Completion
    2005-06
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPanic Disorder
    Interventionparoxetine + aerobic exercise; Paroxetine + relaxation; Placebo + aerobic exercise; Placebo + relaxation
    PhasePhase 4
    Registry statusCompleted

  • A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria

    NCT00516113 · start 2000-10

    Registered record
    Registry ID
    NCT00516113
    Conditions
    Premenstrual Dysphoric Disorder; Premenstrual Syndrome
    Interventions
    paroxetine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2000-10
    Completion
    2002-11
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPremenstrual Dysphoric Disorder; Premenstrual Syndrome
    Interventionparoxetine
    PhasePhase 4
    Registry statusCompleted

  • Sleep Deprivation Plus Paroxetine for Treating Major Depression in Elderly Individuals

    NCT00178035 · start 1999-12

    Registered record
    Registry ID
    NCT00178035
    Conditions
    Depression
    Interventions
    paroxetine; One night of Total Sleep Deprivation
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    1999-12
    Completion
    2003-08
    Enrolment
    158

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    Interventionparoxetine; One night of Total Sleep Deprivation
    PhasePhase 4
    Registry statusCompleted

  • Biological Aspects of Depression and Antidepressant Drugs

    NCT00018733 · start 1996-09

    Registered record
    Registry ID
    NCT00018733
    Conditions
    Depression
    Interventions
    paroxetine; Desipramine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1996-09
    Completion
    2001-12
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    Interventionparoxetine; Desipramine
    PhaseNot applicable
    Registry statusCompleted

  • Luteal Phase Administration of Paroxetine for the Treatment of PMDD

    NCT00620581

    Registered record
    Registry ID
    NCT00620581
    Conditions
    Premenstrual Dysphoric Disorder
    Interventions
    Paroxetine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPremenstrual Dysphoric Disorder
    InterventionParoxetine
    PhasePhase 3
    Registry statusCompleted